Rigel Pharmaceuticals(RIGL)
SOUTH SAN FRANCISCO, CA
PharmaceuticalFocus: Small Molecules
Rigel Pharmaceuticals is a life sciences company focused on Small Molecules.
Neurology
Funding Stage
PUBLIC
Open Jobs
0
Products & Portfolio (3)
Pipeline & Clinical Trials
Fostamatinib disodium 100 mg
Immune Thrombocytopenic PurpuraClinical Trials (1)
NCT03363334Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP
N/AFostamatinib
ITPClinical Trials (1)
NCT04904276Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
N/AR348 Ophthalmic Solution, 0.2%
Keratoconjunctivitis SiccaClinical Trials (1)
NCT01733992A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease
Phase 1Fostamatinib
Chronic Graft Versus Host DiseaseClinical Trials (1)
NCT06233110Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
Phase 1Fostamatinib in combination with chemotherapy
Pancreatic Ductal Adenocarcinoma (PDAC)Clinical Trials (1)
NCT06639724Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
Phase 1Olutasidenib Investigational Agent Administration
Acute Myeloid LeukemiaClinical Trials (1)
NCT07130695Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
Phase 1Fostamatinib 100 mg bid and Paclitaxel
Ovarian CancerClinical Trials (1)
NCT03246074Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Phase 1R906289 Monosodium
Low Risk Myelodysplastic SyndromesClinical Trials (1)
NCT05308264Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Phase 1/2Ruxolitinib
CoronavirusOlutasidenib
Mutant IDH1 Inhibitor OlutasidenibClinical Trials (1)
NCT06445959Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
Phase 1/2fostamatinib
LymphomaClinical Trials (1)
NCT00446095Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma
Phase 1/2Phase 2
Clinical Trials (1)
NCT06564207Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults
Phase 2Placebo
AsthmaClinical Trials (1)
NCT01591044A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
Phase 2Fostamatinib disodium
Rheumatoid ArthritisClinical Trials (1)
NCT00665626Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)
Phase 2R348 Ophthalmic Solution, 0.2%
Keratoconjunctivitis SiccaClinical Trials (1)
NCT01900249To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Phase 2Fostamatinib 150 mg bid
Warm Antibody Autoimmune Hemolytic AnemiaClinical Trials (1)
NCT02612558A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)
Phase 2Olutasidenib + TMZ
High Grade GliomaClinical Trials (1)
NCT06161974Study of Olutasidenib and Temozolomide in HGG
Phase 2Olutasidenib
Targeted TherapyClinical Trials (1)
NCT07032727Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Phase 2Fostamatinib Disodium tablet 100 mg
IGA NephropathyClinical Trials (1)
NCT02433236Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
Phase 2LY3871801
Rheumatoid ArthritisFostamatinib Disodium
Systemic Lupus ErythematosusClinical Trials (1)
NCT00752999Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus
Phase 2R932333
Lupus Erythematosus, DiscoidClinical Trials (1)
NCT01597050Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
Phase 2Fostamatinib Disodium / R935788
Purpura, Thrombocytopenic, IdiopathicClinical Trials (1)
NCT00706342Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
Phase 2Phase 2
Clinical Trials (1)
NCT00326339Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)
Phase 2Olutasidenib
Acute Myeloid LeukemiaClinical Trials (1)
NCT06782542Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
Phase 2Olutasidenib
Myelodysplastic SyndromesClinical Trials (1)
NCT06566742A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Phase 2R926112
Rhinitis, Allergic, SeasonalClinical Trials (1)
NCT001150897 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis
Phase 2Fostamatinib disodium
Rheumatoid ArthritisClinical Trials (1)
NCT00665925Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis
Phase 2Fostamatinib
MyelofibrosisClinical Trials (1)
NCT04543279Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
Phase 2Fostamatinib Disodium
T Cell LymphomaClinical Trials (1)
NCT00798096Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
Phase 2Fostamatinib
Hidradenitis SuppurativaClinical Trials (1)
NCT05040698Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa
Phase 2Olutasidenib
Chronic Myelomonocytic LeukemiaClinical Trials (1)
NCT06597734A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Phase 2Fostamatinib 150 mg
IGA NephropathyClinical Trials (1)
NCT02112838Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
Phase 2R348 Ophthalmic Solution, 0.2%
Chronic Graft-versus-host DiseaseClinical Trials (1)
NCT02040623Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
Phase 2Fostamatinib
Covid19Clinical Trials (1)
NCT04629703Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Phase 3Fostamatinib disodium
Warm Antibody Autoimmune Hemolytic AnemiaClinical Trials (1)
NCT04138927A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Phase 3Fostamatinib disodium
Immune Thrombocytopenic PurpuraClinical Trials (1)
NCT02076399A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Phase 3Fostamatinib Disodium
Immune Thrombocytopenic PurpuraClinical Trials (1)
NCT02076412A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Phase 3Fostamatinib Disodium
Immune Thrombocytopenic PurpuraClinical Trials (1)
NCT02077192Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Phase 3Fostamatinib disodium
Warm Antibody Autoimmune Hemolytic AnemiaClinical Trials (1)
NCT03764618A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
Phase 3imiquimod 5% cream
Actinic KeratosesClinical Trials (1)
NCT00774787Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses
Phase 4Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 3 approved products, 39 clinical trials
Top TAs: Oncology
SEC Filings: 2 available
Portfolio Health
Peak3 (100%)
3 total products
Financials (FY2025)
Revenue
$117M3%
R&D Spend
$25M(21%)59%
Net Income
-$25MCash
$57M